Rating Scale devised for HSP

Posted - March 2007 in Living with HSP - Management & Treatment News

The Spastic Paraplegia Rating Scale – a reliable and valid measure of disease severity

German scientists have successfully developed and tested a 13-item scale designed to rate functional impairment occurring in pure forms of spastic paraplegia.  The clinical Spastic Paraplegia Rating Scale (SPRS) measures disease severity and progression.  It is hoped that the availability of the SPRS will make the choice of management and treatment options that much more scientific and precise.

In 2003 the German Network for Hereditary Movement Disorders (GeNeMove) was founded to research rare genetic movement disorders in Germany.  The SPRS is the result of a collaboration between movement disorder specialists – the GeNeMove SP task force – from six German universities.  Sixty-three patients from 50 families were recruited for the trial in seven GeNeMove SP outpatient clinics.  The rating requires less than 15 minutes to complete and requires no special equipment, so it is suitable in an outpatient setting.

Scientifically rigorous and clinically meaningful rating scales are essential to measure treatment impact, especially in diseases in which conventional laboratory markers of disease activity are missing, which is the case with HSP.

The full article is available at:

http://www.neurology.org/content/vol67/issue3/

Scroll down the page until you locate “The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity” and choose from the options offered.

The final version of the scale itself is available on the Neurology Web site at:

http://www.neurology.org/cgi/content/full/67/3/430/DC1

Click on E1 to download the scale (Word document; 44KB)

SOURCE: Neurology. 2006 Aug 8;67(3):430-4

The Spastic Paraplegia Rating Scale (SPRS): a reliable
and valid measure of disease severity

Schule R, Holland-Letz T, Klimpe S, Kassubek J,
Klopstock T, Mall V, Otto S, Winner B, Schols L.

Hertie Institute for Clinical Brain Research and
Department of Neurology, Eberhard Karls University
Tubingen, Germany.